Author correction: tumour gene expression signature in primary melanoma predicts long-term outcomes

Correction to: _Nature Communications_ https://doi.org/10.1038/s41467-021-21207-2, published online 18 February 2021. The original version of this article used a registered trademark name to

indicate the 27 genes that comprise the ‘DecisionDx-Melanoma’ test; which was incorrect References to the gene signature derived from these genes have been amended and are now referred to

as the ‘Gerami_27’ gene signature. In particular: In the fourth paragraph of the Results section “Signature added incremental prognostic value when combined with conventional clinical

staging” the sentence “The published signature from Gerami et al.12 (Decision-Dx MelanomaTM; _n_ = 27 genes) was not associated with OS in multivariate models in the AVAST-M primary melanoma

dataset” has been replaced with “The published signature from Gerami et al.12 (Gerami_27; _n_ = 27 genes) was not associated with OS in multivariate models in the AVAST-M primary melanoma

dataset”. In the third paragraph of the Results section “Cam_121 predicts metastasis better than both clinical covariates and published prognostic signatures” the sentence “In order to test

the performance of the published prognostic signatures from Gerami et al. (Decision-Dx MelanomaTM; _n_ = 27 genes) and Thakur et al.” has been replaced with “In order to test the performance

of the published prognostic signatures from Gerami et al. (Gerami_27; _n_ = 27 genes) and Thakur et al.”. In the same section in the last line “Cam_121 vs Decision-Dx Melanoma” has been

replaced with “Cam_121 vs Gerami_27”. In the first paragraph of the Discussion, the sentence “The 31-GEP assay (Decision-Dx MelanomaTM, Castle Biosciences) has been developed in an attempt

to address this clinical dilemma” has been replaced with “The 31-GEP assay (Gerami_27) has been developed in an attempt to address this clinical dilemma”. In the first paragraph of Methods

section “Model development and selection”, the sentence “We also compared this to the predictive power of two published prognostic signatures (LMC_150 and Decision-Dx Melanoma” has been

replaced with “We also compared this to the predictive power of two published prognostic signatures (LMC_150 and Gerami_27’ in an independent analysis”. In Fig. 3e, Decision-Dx’ has been

replaced with: ‘Gerami_27’ and in the associated legend: the sentence “Decision-Dx Melanoma: Decision-Dx MelanomaTM, LMC_150: Leeds Melanoma Cohort 150 gene signature” has been replaced with

“Gerami_27, LMC_150: Leeds Melanoma Cohort 150 gene signature”. The original reference 12 “Gerami, P. et al. Gene expression profiling for molecular staging of cutaneous melanoma in

patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol 72, 780-5.e3 (2015)” has been replaced with “Gerami, P. et al. Development of a prognostic genetic signature to predict the

metastatic risk associated with cutaneous melanoma. Clin Cancer Res 21, 175-183 (2015). In Supplementary Fig. 6a the _x_-axis label ‘Decision-Dx’ has been replaced with ‘Gerami_27’. The

title of Supplementary Fig. 6a has been updated to read ‘Forest plot of univariate and multivariate survival analysis for the two previously published signatures (Gerami_27 and LMC_150). In

the legend to Supplementary Figure 6a the sentence that previously read ‘Forest plot indicating the hazard ratio (HR) estimates (dots at the centre of error bars), corresponding to 95%

confidence intervals of the HR estimates (horizontal error bars) and two-sided Wald t-test p-values related to the signature parameter when considering the signature definitions of a) Gerami

and b) LMC_150 when predicting overall survival (green) and progression free survival (orange) by means of Cox proportional hazard models when controlling for different (sets of) clinical

variables (y-axes)’ has been updated to read ‘Forest plot indicating the hazard ratio (HR) estimates (dots at the centre of error bars), corresponding to 95% confidence intervals of the HR

estimates (horizontal error bars) and two-sided Wald t-test p-values related to the signature parameter when considering the signature definitions of a) Gerami_27 and b) LMC_150 when

predicting overall survival (green) and progression free survival (orange) by means of Cox proportional hazard models when controlling for different (sets of) clinical variables (y-axes). In

row 4 of Supplementary Tables 2c ‘Decision-Dx’ has been replaced with ‘Gerami_27’. In addition, the original Supplementary Fig. 3a and Supplementary Fig. 15 (top) contained a typographical

error and ‘no distant recurrence, 89’ has been replaced with ‘no distant recurrence, 105’. The text and the main figures have been corrected in both the PDF and HTML versions of the Article.

The HTML has been updated to include a corrected version of the Supplementary Information. AUTHOR INFORMATION Author notes * These authors contributed equally: David J. Adams, Alvis Brazma,

Roy Rabbie. AUTHORS AND AFFILIATIONS * European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridgeshire, UK Manik Garg & Alvis Brazma *

Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, UK Dominique-Laurent Couturier * University of Leeds School of Medicine, Leeds,

United Kingdom Jérémie Nsengimana, Julia Newton-Bishop & D. Timothy Bishop * Biostatistics Research Group, Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle

University, Newcastle upon Tyne, UK Jérémie Nsengimana * CIBIO/InBIO-Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Rua Padre Armando Quintas,

4485-601, Vairão, Portugal Nuno A. Fonseca * Oncology Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA Matthew Wongchenko & Yibing Yan * Lund

University Cancer Center, Lund University, Lund, Sweden Martin Lauss & Göran B. Jönsson * Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Christine Parkinson, Pippa Corrie & Roy Rabbie * Oxford NIHR Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK Mark R. Middleton * Department of

Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK Sarah McDonald, Nikki Stefanos & John Tadross * Melanoma Institute Australia, The University of Sydney,

North Sydney, NSW, Australia Ismael A. Vergara, Serigne Lo, James S. Wilmott, John F. Thompson, Georgina V. Long & Richard A. Scolyer * Faculty of Medicine and Health, The University of

Sydney, Sydney, NSW, Australia Ismael A. Vergara, Serigne Lo, James S. Wilmott, John F. Thompson, Georgina V. Long & Richard A. Scolyer * Institute for Research and Medical Consultations

(IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia Serigne Lo * QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia Felicity Newell * Discipline of

Surgery, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia John F. Thompson * Royal North Shore and Mater Hospitals, Sydney, Australia Georgina V. Long *

Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and New South Wales Health Pathology, Sydney, NSW, Australia Richard A. Scolyer * Experimental Cancer Genetics, The

Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK David J. Adams & Roy Rabbie Authors * Manik Garg View author publications You can also search for this author inPubMed Google

Scholar * Dominique-Laurent Couturier View author publications You can also search for this author inPubMed Google Scholar * Jérémie Nsengimana View author publications You can also search

for this author inPubMed Google Scholar * Nuno A. Fonseca View author publications You can also search for this author inPubMed Google Scholar * Matthew Wongchenko View author publications

You can also search for this author inPubMed Google Scholar * Yibing Yan View author publications You can also search for this author inPubMed Google Scholar * Martin Lauss View author

publications You can also search for this author inPubMed Google Scholar * Göran B. Jönsson View author publications You can also search for this author inPubMed Google Scholar * Julia

Newton-Bishop View author publications You can also search for this author inPubMed Google Scholar * Christine Parkinson View author publications You can also search for this author inPubMed

 Google Scholar * Mark R. Middleton View author publications You can also search for this author inPubMed Google Scholar * D. Timothy Bishop View author publications You can also search for

this author inPubMed Google Scholar * Sarah McDonald View author publications You can also search for this author inPubMed Google Scholar * Nikki Stefanos View author publications You can

also search for this author inPubMed Google Scholar * John Tadross View author publications You can also search for this author inPubMed Google Scholar * Ismael A. Vergara View author

publications You can also search for this author inPubMed Google Scholar * Serigne Lo View author publications You can also search for this author inPubMed Google Scholar * Felicity Newell

View author publications You can also search for this author inPubMed Google Scholar * James S. Wilmott View author publications You can also search for this author inPubMed Google Scholar *

John F. Thompson View author publications You can also search for this author inPubMed Google Scholar * Georgina V. Long View author publications You can also search for this author

inPubMed Google Scholar * Richard A. Scolyer View author publications You can also search for this author inPubMed Google Scholar * Pippa Corrie View author publications You can also search

for this author inPubMed Google Scholar * David J. Adams View author publications You can also search for this author inPubMed Google Scholar * Alvis Brazma View author publications You can

also search for this author inPubMed Google Scholar * Roy Rabbie View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to

Roy Rabbie. SUPPLEMENTARY INFORMATION UPDATED SUPPLEMENTARY DATA RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License,

which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link

to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless

indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or

exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints

and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Garg, M., Couturier, DL., Nsengimana, J. _et al._ Author Correction: Tumour gene expression signature in primary melanoma predicts

long-term outcomes. _Nat Commun_ 13, 2841 (2022). https://doi.org/10.1038/s41467-022-30365-w Download citation * Published: 17 May 2022 * DOI: https://doi.org/10.1038/s41467-022-30365-w

SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to

clipboard Provided by the Springer Nature SharedIt content-sharing initiative